Guggenheim maintains a “Buy” rating for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) despite challenges, including the delayed regulatory submissions of Itepekimab.
The delay in Itepekimab’s approval has significantly impacted Regeneron’s growth prospects, contributing to an 18.57% decrease in stock price.
Regeneron’s market capitalization stands at approximately $52.33 billion, with a trading volume of 4,779,116 shares, indicating active investor interest.
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is a biotechnology company renowned for its innovative approach to drug development, especially in the field of monoclonal antibodies. The company collaborates with pharmaceutical giants like Sanofi to bolster its research and development capabilities. Despite facing stiff competition from other biotech firms such as Amgen and Biogen, Regeneron continues to be a key player in the biotechnology sector.
On May 30, 2025, Guggenheim reaffirmed its “Buy” rating for Regeneron, with the stock priced at approximately $490.24. However, the recommendation to “hold” signals caution among investors, primarily due to the inconsistent phase 3 results of Itepekimab, a drug developed in partnership with Sanofi. These results have postponed regulatory submissions by 3 to 4 years, adversely affecting Regeneron’s growth trajectory.
The setback with Itepekimab marks a significant hurdle for Regeneron, as the drug was anticipated to be a major growth driver. The delay in its approval implies that potential peak sales for the drug are now expected to be lower than initially forecasted. This development has played a role in the stock’s recent downturn, with a notable decrease of 18.57%, or $112.40, bringing the current price to $492.99.
Regeneron’s stock has shown volatility, with today’s price fluctuating between a low of $485.04 and a high of $519.78. Over the past year, the stock reached a peak of $1,211.20, showcasing significant market fluctuations. The company’s market capitalization of approximately $52.33 billion underscores its significant footprint in the biotechnology industry.
The trading volume for Regeneron today stands at 4,779,116 shares, indicating a keen interest from investors despite the recent setbacks. As the company moves forward, its future performance will likely hinge on its ability to navigate regulatory challenges and continue its path of innovative drug development.
